Compare Acadia Healthcare Company Inc (ACHC) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs BridgeBio Pharma Inc — how do they compare? Acadia Healthcare Company Inc trades at $28.13 (market cap $2.68B), while BridgeBio Pharma Inc trades at $66.12 (market cap $13.16B). The key difference: BridgeBio Pharma Inc is far larger — about 4.9× Acadia Healthcare Company Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Acadia Healthcare Company Inc for 8 Days and BridgeBio Pharma Inc for 63 Days on average.
| ACHC | BBIO | |
|---|---|---|
Market Cap | $2.68B | $13.16B |
Volume | 1,474,853 | 2,332,775 |
Sector | Health | Health |
52-Week High | $35.61 | $90.17 |
52-Week Low | $11.68 | $49.00 |
Typical Hold Time | 8 Days | 63 Days |
Enterprise Value | $5.08B | $14.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $29.09, up 3.3% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong revenue growth but faces profitability challenges with a -33.44% net income margin. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a $34.43 consensus price target representing 18% upside potential. Institutional interest is strong with BlackRock taking a $441.69 million position in Q2 2026.
The outlook balances growth potential against profitability concerns. Expansion in behavioral healthcare facilities and strong demand support upside, but negative returns and ongoing legal investigations present significant risks. The stock offers potential for price appreciation if profitability improves, but investors face execution and regulatory uncertainties.
BridgeBio Pharma (BBIO) trades at $68.3, down 0.13% on the day, with a bearish technical signal despite bullish oscillators like RSI. Revenue growth is strong, with 2025 revenue at $502.08M, but the company remains deeply unprofitable with a net income margin of -144.39%. Recent news highlights clinical successes for acoramidis and infigratinib, alongside active participation in investor conferences.
The outlook hinges on commercial execution and pipeline catalysts to justify its premium P/S of 18.31. Analyst consensus is strongly bullish with a $110.09 price target, but significant risks include persistent cash burn, high debt, and the challenge of achieving profitability amid substantial operating losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
